Valacyclovir Dosing for Recurrent HSV-1 and HSV-2
Episodic Treatment of Recurrent Outbreaks
For recurrent episodes of HSV-1 or HSV-2, the recommended dose is valacyclovir 500 mg twice daily for 3-5 days, initiated at the first sign or symptom of an outbreak. 1, 2
- The FDA-approved regimen for recurrent genital herpes is 500 mg twice daily for 3 days 2
- The CDC supports extending treatment to 5 days (500 mg twice daily) as an alternative regimen 1
- Treatment must be initiated at the earliest symptom (tingling, itching, burning) for maximum efficacy 1, 2
Chronic Suppressive Therapy
For patients requiring daily suppression, the dose depends on recurrence frequency:
Standard Suppression (≤9 recurrences per year)
- Valacyclovir 500 mg once daily is the recommended dose for immunocompetent patients with infrequent recurrences 1, 2
- This regimen reduces recurrence frequency by ≥75% 1
High-Frequency Suppression (≥10 recurrences per year)
- Valacyclovir 1000 mg (1 gram) once daily is necessary for patients with frequent recurrences 1, 3, 2
- The 500 mg once-daily dose is significantly less effective in this population and should not be used 1, 3, 4
Special Populations
HIV-Infected Patients
- For HIV-infected patients with CD4+ count ≥100 cells/mm³, use valacyclovir 500 mg twice daily for suppressive therapy 1, 3, 2
- Episodic treatment requires 5-14 days (not the 1-3 day short-course regimens used in immunocompetent patients) 3
Transmission Reduction
- Valacyclovir 500 mg once daily reduces HSV-2 transmission to uninfected partners by 50% in source partners with ≤9 recurrences per year 3
Clinical Considerations
Duration and Monitoring
- Safety and efficacy have been documented for up to 1 year with valacyclovir 1
- After 1 year of continuous suppressive therapy, consider discussing discontinuation to reassess recurrence frequency, as recurrences may decrease over time 1
- No laboratory monitoring is needed unless substantial renal impairment exists 1, 3
Renal Dosing
- For creatinine clearance 30-49 mL/min, no dose reduction is required 1
- Patients with significant renal impairment require dose adjustment and monitoring 1
Treatment Failure
- If lesions persist despite appropriate valacyclovir treatment, suspect HSV resistance 1
- All acyclovir-resistant strains are also resistant to valacyclovir 1, 3
- For acyclovir-resistant HSV, IV foscarnet (40 mg/kg every 8 hours) is the treatment of choice 1
Common Pitfalls to Avoid
- Do not use 500 mg once daily for patients with ≥10 recurrences per year – this dose is inadequate and will result in breakthrough recurrences 1, 3, 4
- Do not use short 1-3 day episodic regimens in HIV-infected patients – they require 5-14 days of treatment 3
- Do not use high-dose valacyclovir (8 g/day) in immunocompromised patients – this has been associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome 1, 5
- Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 1